Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:10534
Name stomach cancer
Definition A gastrointestinal system cancer that is located_in the stomach.
Source DiseaseOntology.org
Alt Ids DOID:4713 DOID:10542 DOID:10543 DOID:10539
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer stomach cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
MAP2K1 Q56P Selumetinib stomach cancer sensitive detail...
RAD51C loss Olaparib stomach cancer sensitive detail...
Unknown unknown Saracatinib stomach cancer not applicable detail...
FGFR2 amp AZD4547 stomach cancer sensitive detail...
PIK3CA mutant BAY1082439 stomach cancer sensitive detail...
Unknown unknown Cisplatin + Deguelin stomach cancer not applicable detail...
PIK3CA H1047R Capivasertib stomach cancer sensitive detail...
Unknown unknown RX-0201 stomach cancer not applicable detail...
Unknown unknown CUDC-101 stomach cancer not applicable detail...
Unknown unknown JNJ-26483327 stomach cancer not applicable detail...
Unknown unknown Cisplatin + Fluorouracil + Sapitinib stomach cancer not applicable detail...
PTEN del CH5132799 stomach cancer sensitive detail...
FGFR2 wild-type Ponatinib stomach cancer resistant detail...
FGFR2 amp Ponatinib stomach cancer sensitive detail...
FGFR2 amp Dovitinib stomach cancer sensitive detail...
FGFR2 amp Cediranib stomach cancer sensitive detail...
FGFR2 amp Brivanib stomach cancer no benefit detail...
FGFR2 amp FIIN-1 stomach cancer sensitive detail...
FGFR2 amp Selumetinib stomach cancer resistant detail...
FGFR2 amp PD173074 stomach cancer sensitive detail...
FGFR2 amp Infigratinib stomach cancer sensitive detail...
FGFR2 amp Debio 1347 stomach cancer sensitive detail...
PIK3CA mutant Dactolisib stomach cancer sensitive detail...
FGFR2 amp PRN1109 stomach cancer predicted - sensitive detail...
Unknown unknown HD105 stomach cancer not applicable detail...
Unknown unknown AT13148 stomach cancer not applicable detail...
Unknown unknown Geldanamycin stomach cancer not applicable detail...
MAP2K1 Q56P Trametinib stomach cancer sensitive detail...
Unknown unknown LY3164530 stomach cancer not applicable detail...
Unknown unknown Capecitabine + Lapatinib stomach cancer not applicable detail...
Unknown unknown Rivoceranib stomach cancer not applicable detail...
ATM dec exp Veliparib stomach cancer sensitive detail...
Unknown unknown Cetuximab stomach cancer no benefit detail...
Unknown unknown Everolimus stomach cancer no benefit detail...
Unknown unknown Bevacizumab stomach cancer not applicable detail...
Unknown unknown Irinotecan + Nimotuzumab stomach cancer no benefit detail...
Unknown unknown Regorafenib stomach cancer not applicable detail...
Unknown unknown Olaparib + Paclitaxel stomach cancer not applicable detail...
ATM dec exp Olaparib + Paclitaxel stomach cancer predicted - sensitive detail...
Unknown unknown Ipilimumab stomach cancer no benefit detail...
Unknown unknown Avelumab stomach cancer not applicable detail...
Unknown unknown Nivolumab stomach cancer not applicable detail...
Unknown unknown Ipilimumab + Nivolumab stomach cancer not applicable detail...
Unknown unknown PU-H71 stomach cancer not applicable detail...
FGFR2 positive Aprutumab ixadotin stomach cancer sensitive detail...
FGFR2 amp E7090 stomach cancer sensitive detail...
ATM over exp Veliparib stomach cancer decreased response detail...
ATM over exp Irinotecan + Veliparib stomach cancer sensitive detail...
ATM over exp Irinotecan stomach cancer decreased response detail...
FGFR2 amp FGFR2 over exp Infigratinib stomach cancer sensitive detail...
FGFR2 amp FGFR2 over exp AZD4547 stomach cancer sensitive detail...
Unknown unknown Chiauranib stomach cancer not applicable detail...
Unknown unknown AZD6738 + Paclitaxel stomach cancer not applicable detail...
Unknown unknown AZD6738 + Cisplatin stomach cancer not applicable detail...
Unknown unknown Doxorubicin + Tozasertib stomach cancer not applicable detail...
Unknown unknown OPB-111077 stomach cancer not applicable detail...
FGFR2 amp Erdafitinib stomach cancer sensitive detail...
Unknown unknown LY2874455 stomach cancer not applicable detail...
PIK3CA mutant MLN1117 stomach cancer predicted - sensitive detail...
FGFR2 amp Futibatinib stomach cancer predicted - sensitive detail...
FGFR3 positive Rogaratinib stomach cancer predicted - sensitive detail...
Unknown unknown DKN-01 + Paclitaxel stomach cancer not applicable detail...
PIK3CA E545K PTEN loss Sirolimus stomach cancer unknown detail...
PIK3CA E542K PTEN loss Sirolimus stomach cancer unknown detail...
ATM negative Olaparib + Paclitaxel stomach cancer no benefit detail...
MLH1 mutant N/A stomach cancer not applicable detail...
FGFR2 fusion FGFR2 amp Derazantinib stomach cancer sensitive detail...
FGFR2 amp Derazantinib stomach cancer sensitive detail...
Unknown unknown Camrelizumab stomach cancer not applicable detail...
Unknown unknown Trifluridine-tipiracil hydrochloride stomach cancer not applicable detail...
Unknown unknown Camrelizumab + Rivoceranib stomach cancer not applicable detail...
FGFR2 amp ODM-203 stomach cancer sensitive detail...
Unknown unknown Capecitabine + Oxaliplatin + Toripalimab stomach cancer not applicable detail...
Unknown unknown Mogamulizumab + Nivolumab stomach cancer not applicable detail...
Unknown unknown OBI-999 stomach cancer not applicable detail...
FGFR2 - WDR11 Infigratinib stomach cancer sensitive detail...
Unknown unknown Capecitabine + Nivolumab + Oxaliplatin + Tegafur-gimeracil-oteracil Potassium stomach cancer not applicable detail...
FGFR2 amp Pictilisib stomach cancer no benefit detail...
FGFR2 amp MK2206 stomach cancer no benefit detail...
Unknown unknown Capmatinib stomach cancer not applicable detail...
PIK3CA E545K Capivasertib stomach cancer sensitive detail...
PIK3CA E542K Capivasertib stomach cancer sensitive detail...
FGFR2 amp Regorafenib stomach cancer sensitive detail...
Unknown unknown Atezolizumab + BKT140 stomach cancer no benefit detail...
Unknown unknown Envafolimab + Fluorouracil + Leucovorin + Oxaliplatin stomach cancer not applicable detail...
Unknown unknown MGD013 stomach cancer not applicable detail...
MSH6 mutant N/A stomach cancer not applicable detail...
Unknown unknown ALX148 + Trastuzumab stomach cancer not applicable detail...
Unknown unknown Lenvatinib + Pembrolizumab stomach cancer not applicable detail...
Unknown unknown Flucytosine + TG6002 stomach cancer not applicable detail...
Unknown unknown IGM-8444 stomach cancer not applicable detail...
Unknown unknown CAT-01-106 stomach cancer not applicable detail...
Unknown unknown Fluorouracil + Ipatasertib + Leucovorin + Oxaliplatin stomach cancer no benefit detail...
PTEN dec exp Fluorouracil + Ipatasertib + Leucovorin + Oxaliplatin stomach cancer no benefit detail...
Unknown unknown Rivoceranib + Tegafur-gimeracil-oteracil Potassium stomach cancer no benefit detail...
Unknown unknown AK963 stomach cancer not applicable detail...
FGFR1 over exp Regorafenib stomach cancer sensitive detail...
FGFR1 over exp Infigratinib stomach cancer sensitive detail...
FGFR1 over exp Futibatinib stomach cancer sensitive detail...
FGFR1 over exp Erdafitinib stomach cancer sensitive detail...
FGFR2 amp FGFR2 over exp Regorafenib stomach cancer no benefit detail...
FGFR2 amp Regorafenib + Trametinib stomach cancer sensitive detail...
FGFR2 amp Infigratinib + Trametinib stomach cancer sensitive detail...
FGFR1 over exp Regorafenib + Trametinib stomach cancer sensitive detail...
FGFR1 over exp Infigratinib + Trametinib stomach cancer sensitive detail...
Unknown unknown Capecitabine + Nivolumab + Oxaliplatin stomach cancer not applicable detail...
Unknown unknown Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin stomach cancer not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01037790 Phase II Palbociclib PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Completed USA 0
NCT01148849 Phase I Margetuximab-cmkb Safety Study of MGAH22 in HER2-positive Carcinomas Active, not recruiting USA 1
NCT01325441 Phase Ib/II Napabucasin + Paclitaxel A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Active, not recruiting USA | CAN 0
NCT01468922 Phase I Tivantinib Pazopanib Pazopanib and ARQ 197 for Advanced Solid Tumors Completed USA 0
NCT01522768 Phase II Afatinib + Paclitaxel Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer Active, not recruiting USA 0
NCT01576666 Phase Ib/II Buparlisib + Sonidegib Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Completed USA | CAN 6
NCT01602406 Phase I Elgemtumab + Trastuzumab Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer Completed USA 8
NCT01641939 Phase III Docetaxel Paclitaxel Ado-trastuzumab emtansine A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer Terminated USA | CAN 26
NCT01702558 Phase II Ado-trastuzumab emtansine Ado-trastuzumab emtansine + Capecitabine A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer Terminated CAN 11
NCT01928290 Phase II Trastuzumab Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer Completed USA 0
NCT01928394 Phase Ib/II Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Active, not recruiting USA | CAN 6
NCT01938638 Phase I BAY1143572 Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Completed USA 3
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Recruiting USA | CAN 13
NCT01989546 Phase Ib/II Talazoparib Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations Completed USA 0
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed USA 0
NCT02047747 Phase II Dacomitinib A Phase II Study of Dacomitinib in Progressive Brain Metastases Terminated USA 0
NCT02122809 Phase I Chiauranib Phase I Study of Chiauranib in Patients With Advanced Solid Tumors Completed 1
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02281409 Phase Ib/II Mogamulizumab Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors Completed USA 0
NCT02310464 Phase I OBI-821 + OBI-833 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects Completed 1
NCT02314117 Phase III Capecitabine Fluorouracil Cisplatin Ramucirumab A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Completed USA | CAN 18
NCT02315066 Phase I PF-04518600 PF-04518600 + Utomilumab Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Completed USA 3
NCT02318901 Phase Ib/II Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer Terminated USA 0
NCT02323191 Phase I Atezolizumab + Emactuzumab A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors Completed USA 3
NCT02341625 Phase Ib/II BMS-986148 BMS-986148 + Nivolumab A Study of BMS-986148 in Patients With Select Advanced Solid Tumors Active, not recruiting USA | CAN 5
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated USA 1
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Active, not recruiting USA 1
NCT02404441 Phase Ib/II Spartalizumab Phase I/II Study of PDR001 in Patients With Advanced Malignancies Completed USA | CAN 12
NCT02443883 Phase II Ramucirumab A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer Completed USA 11
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Terminated USA 0
NCT02460224 Phase Ib/II LAG525 Spartalizumab Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Completed USA | CAN 10
NCT02471846 Phase I GDC-0919 Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Completed USA 3
NCT02500199 Phase I Pyrotinib Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors Active, not recruiting USA 0
NCT02554812 Phase Ib/II Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Recruiting USA | CAN 6
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated USA 0
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed 3
NCT02631733 Phase I Irinotecan + Veliparib Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Suspended USA 0
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting USA 0
NCT02658214 Phase I Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors Completed 2
NCT02660034 Phase I Pamiparib + Tislelizumab The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Completed USA 5
NCT02734004 Phase Ib/II Durvalumab + Olaparib Bevacizumab + Durvalumab + Olaparib A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) Active, not recruiting USA 6
NCT02744287 Phase Ib/II BPX-601 + Rimiducid Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors Recruiting USA 0
NCT02760797 Phase I Emactuzumab + Selicrelumab A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Completed USA 2
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed USA 5
NCT02872116 Phase III Capecitabine + Oxaliplatin Ipilimumab + Nivolumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649) Active, not recruiting USA | CAN 27
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Completed USA 0
NCT02900651 Phase Ib/II MAK683 Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies Recruiting USA | CAN 7
NCT02935634 Phase II Nivolumab + Relatlimab Ipilimumab + Nivolumab A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC) Recruiting USA | CAN 9
NCT02952248 Phase I BI 754091 A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Active, not recruiting USA | CAN 1
NCT02952729 Phase I XMT-1522 Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 Completed USA 0
NCT02960594 Phase I INO-1400 + INO-9012 INO-1400 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Completed USA 0
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Recruiting USA 0
NCT02965885 Phase I Pimitespib A Study of TAS-116 in Patients With Solid Tumors Completed USA 2
NCT02970539 Phase I Oraxol + Ramucirumab Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers Active, not recruiting USA 1
NCT02977156 Phase I Ipilimumab + JX-594 Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (ISI-JX) Recruiting 1
NCT03126110 Phase Ib/II INCAGN01876 + Ipilimumab + Nivolumab INCAGN01876 + Nivolumab INCAGN01876 + Ipilimumab Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies Active, not recruiting USA 4
NCT03132922 Phase I ADP-A2M4 cells MAGE-A4c1032T for Multi-Tumor Recruiting USA | CAN 0
NCT03150810 Phase Ib/II Pamiparib + Temozolomide Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA 3
NCT03172416 Phase I Nivolumab + Oxaliplatin Oxaliplatin Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal Carcinomatosis (PIPAC) Recruiting 3
NCT03284723 Phase I Letrozole + Palbociclib + PF-06804103 PF-06804103 PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors Active, not recruiting USA 5
NCT03319459 Phase I FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting USA 0
NCT03330561 Phase I PRS-343 PRS-343 in HER2-Positive Solid Tumors Recruiting USA 0
NCT03342417 Phase II Ipilimumab + Nivolumab Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients Terminated USA 0
NCT03410927 Phase Ib/II TAS0728 A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Active, not recruiting USA 3
NCT03416335 Phase Ib/II DSP-0509 DSP-0509 + Pembrolizumab A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile Recruiting USA 0
NCT03448042 Phase I BTRC 4017A A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers Recruiting USA | CAN 11
NCT03511222 Phase I Pembrolizumab + Vorolanib Nivolumab + Vorolanib Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors Terminated USA 0
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Active, not recruiting USA 0
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Completed USA | CAN 1
NCT03602079 Phase Ib/II A166 Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Recruiting USA 0
NCT03610711 Phase Ib/II Nivolumab + Relatlimab Nivolumab REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (REACTION) Recruiting USA 0
NCT03621982 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Recruiting USA 0
NCT03629756 Phase I AB928 + GLS-010 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Active, not recruiting USA 1
NCT03653507 Phase III Capecitabine + Oxaliplatin Capecitabine + Oxaliplatin + Zolbetuximab A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW) Recruiting USA | CAN 17
NCT03662659 Phase II Nivolumab + Relatlimab + Tegafur-gimeracil-oteracil Potassium Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + Relatlimab Nivolumab + Tegafur-gimeracil-oteracil Potassium Capecitabine + Nivolumab + Oxaliplatin Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Capecitabine + Nivolumab + Oxaliplatin + Relatlimab An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers Active, not recruiting USA | CAN 15
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting USA 5
NCT03694249 Phase II Ifetroban sodium Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence Recruiting USA 0
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Terminated USA 0
NCT03704077 Phase II Nivolumab Paclitaxel + Ramucirumab Nivolumab + Paclitaxel Nivolumab + Paclitaxel + Relatlimab Nivolumab + Relatlimab An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Trherapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cance or Gastroesophageal Junction Adenocarcinoma Withdrawn USA | CAN 12
NCT03720678 Phase I AB928 + Fluorouracil + Leucovorin + Oxaliplatin A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal (GI) Malignancies Active, not recruiting USA 1
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Recruiting USA | CAN 13
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Recruiting USA 0
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Recruiting USA 3
NCT03847168 Phase I KN026 KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer Recruiting USA 0
NCT03872947 Phase I Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 Fluorouracil + Irinotecan + Leucovorin + TRK-950 A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Recruiting USA 1
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Active, not recruiting USA 4
NCT03973333 Phase Ib/II Atezolizumab + IMC-C103C IMC-C103C Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab Recruiting USA 2
NCT03993873 Phase I TPX-0022 Phase 1 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET Recruiting USA 3
NCT04014075 Phase II Trastuzumab deruxtecan DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02) Active, not recruiting USA 4
NCT04044859 Phase I ADP-A2M4 cells Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors Recruiting USA | CAN 2
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Recruiting USA 1
NCT04068896 Phase I NGM120 Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy Recruiting USA 0
NCT04082364 Phase II Fluorouracil + Leucovorin + Margetuximab-cmkb + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab Capecitabine + Margetuximab-cmkb + Oxaliplatin + Retifanlimab Margetuximab-cmkb + Retifanlimab Capecitabine + Margetuximab-cmkb + MGD013 + Oxaliplatin Capecitabine + Oxaliplatin + Trastuzumab Fluorouracil + Leucovorin + Margetuximab-cmkb + Oxaliplatin + Retifanlimab Capecitabine + Margetuximab-cmkb + Oxaliplatin Fluorouracil + Leucovorin + Margetuximab-cmkb + MGD013 + Oxaliplatin Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY) Recruiting USA 7
NCT04095273 Phase I BAY1895344 + Pembrolizumab Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Recruiting USA 4
NCT04147819 Phase I BAY2701439 A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein Recruiting USA 1
NCT04152018 Phase I PF-06801591 + PF-06940434 PF-06940434 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Recruiting USA 0
NCT04189445 Phase II Futibatinib Futibatinib in Patients With Specific FGFR Aberrations Recruiting USA 13
NCT04209686 Phase II Olaparib + Paclitaxel + Pembrolizumab Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma Recruiting USA 0
NCT04225117 Phase II Enfortumab vedotin-ejfv A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) Recruiting USA 1
NCT04246671 Phase Ib/II TAEK-VAC-HerBy TAEK-VAC-HerBy + unspecified ERBB2 antibody + unspecified immune checkpoint inhibitor Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients Recruiting USA 0
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT04259450 Phase Ib/II AFM24 Study to Assess AFM24 in Advanced Solid Cancers Recruiting USA 2
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04282044 Phase I CRX100 Study of CRX100 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04294576 Phase I BJ-001 + Pembrolizumab BJ-001 Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) Recruiting USA 0
NCT04319757 Phase I ACE1702 + Cyclophosphamide + Fludarabine ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors Recruiting USA 0
NCT04344795 Phase I TPST-1495 Pembrolizumab + TPST-1495 Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors Recruiting USA 0
NCT04383938 Phase Ib/II APR-246 + Pembrolizumab Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies Recruiting USA 0
NCT04389632 Phase I SGN-B6A A Study of SGN-B6A in Advanced Solid Tumors Recruiting USA 3
NCT04396821 Phase I TST001 A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT04421820 Phase I BOLD-100 + Fluorouracil + Leucovorin + Oxaliplatin BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours Recruiting CAN 0
NCT04423029 Phase Ib/II DF6002 + Pembrolizumab DF6002 Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Recruiting USA 0
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Recruiting USA | CAN 0
NCT04467515 Phase Ib/II CAM-H2 A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer Recruiting CAN 0
NCT04504669 Phase I AZD8701 + Durvalumab AZD8701 First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours Recruiting USA | CAN 2
NCT04505839 Phase I STP1002 First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors Recruiting USA 0
NCT04550494 Phase II Talazoparib Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Recruiting USA 0
NCT04561362 Phase Ib/II BT8009 BT8009 + Nivolumab Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies Recruiting USA 3
NCT04714983 Phase I DNX-2440 DNX-2440 for Resectable Colorectal Liver Metastasis Recruiting USA 0
NCT04772989 Phase I AB308 + GLS-010 A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies Recruiting USA 0
NCT04795661 Phase II Pembrolizumab Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP) Not yet recruiting 1
NCT04847466 Phase II ALT-803 + PD-L1.t-haNK cells + Pembrolizumab Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer Not yet recruiting USA 0